BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mailavaram RP, Al-attraqchi OH, Kar S, Ghosh S. Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents. CPD 2019;25:2772-87. [DOI: 10.2174/1381612825666190716114056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mazziotta C, Rotondo JC, Lanzillotti C, Campione G, Martini F, Tognon M. Cancer biology and molecular genetics of A3 adenosine receptor. Oncogene 2021. [PMID: 34750517 DOI: 10.1038/s41388-021-02090-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
2 Deb PK. Therapeutic Potentials of Adenosine Receptors: The State of The Art. Curr Pharm Des 2019;25:2789-91. [PMID: 31674891 DOI: 10.2174/138161282526191007143942] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Boia R, Ruzafa N, Aires ID, Pereiro X, Ambrósio AF, Vecino E, Santiago AR. Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead. Int J Mol Sci 2020;21:E2262. [PMID: 32218163 DOI: 10.3390/ijms21072262] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 18.5] [Reference Citation Analysis]
4 Deb PK. Progress in the Development of Agonists, Antagonists and Allosteric Modulators of Adenosine Receptors. CPD 2019;25:2695-6. [DOI: 10.2174/138161282525190916100149] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]